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Mary B. Perry, MS,* and Carolyn L. Barth, PhD* 
A 56-year-old man presented with a one-year history of 
progressive weakness predominantly affecting his ex-
tremities and persistent low back pain. OuchteHony 
immunodiffusion of the concentrated urine detected a 
marked increase in lambda light chains. A sternal bone 
marrow documented a diagnosis of multiple myeloma. 
Screening high resolution agarose gel electrophoresis 
revealed diffuse hypogammaglobulinemia and, retro-
spectively, an equivocal, faint band which migrated in 
the fast gamma region. By using a combination of Im-
munoelectrophoresis and immunofixation electro-
phoresis, this questionable band was determined to 
represent an IgE lambda monoclonal protein. Radio-
immunoassay for IgE documented a serum con-
centration of 50.6 mg/dl. No intact IgE was found in the 
urine. Following chemotherapy, the patient's serum IgE 
level decreased significantly, and he is presently 
asymptomatic. 
Features of special interest in this case include the low 
serum IgE level on presentation, which was difficult to 
detect on the screening electrophoretogram, and the 
use of immunofixation electrophoresis in the detection 
and characterization ofthese "difficult" gammopathies. 
IgE myeloma is the rarest and most recently described 
among the plasma cell dyscrasias. This rarity un-
doubtedly reflects the low levei of IgE normally found 
in serum (1) and thus the small number of IgE produc-
ing cells present (2). Since the initial observation by 
Johansson and Bennich in 1967, only 19 cases have been 
reported (3-21), including a case of benign monoclonal 
IgE gammopathy (22) and several other reports where 
monoclonal IgE was associated with other disorders 
(23-26). 
The purpose of this paper is to describe the clinical and 
immunochemical features of this new case of IgE my-
eloma and to compare them wi th the previously re-
ported cases. In addi t ion, the methodology used to 
resolve serum parapro te ins present in low con -
centration wi l l be briefly discussed. 
Case Report 
A 56-year-old Caucasian man presented in March, 1983 
complaining of a one-year history of progressive weak-
ness and tiredness with persistent low back pain, pain in 
both legs and arms, and diff iculty in chewing due to 
extreme jaw weakness. 
His past medical history was remarkable for bilateral 
carpal tunnel syndrome in 1981. There was no history of 
asthma, hay fever, or food allergy. The patient was not 
taking any medication. 
Physical examinat ion was unremarkable except for 
prominent, f i rm temporal and antecubital superficial 
veins bilaterally and mild hepatosplenomegaly. 
Laboratory data included a whi te blood cell count of 
7,700/mm' (71% neutrophi ls , 26% lymphocytes, 2% 
monocytes, 1 % basophils), and a hemoglobin level of 
14.2 g/dl. The platelet count was 416,000/mm\ The 
peripheral b lood smear showed mild anisocytosis wi th-
out rouleau. Blood urea nitrogen was 16 mg/dl, and the 
creatinine level was 1.1 mg/dl. The calcium level was 9.8 
mg/dl, uric acid was 6.1 mg/dl. The total protein level 
was decreased (6.1 g/dl) wi th the albumin level 4.1 g/dl. 
The urinalysis was unremarkable. The creatinine clear-
ance was 138 ml/min. Twenty-four-hour urine protein 
was markedly elevated (5.4 g/vol). Metastatic bone sur-
vey was negative. A sternal bone marrow aspirate dis-
closed normal cellularity wi th 19% mature plasma cells 
and 4.5% proplasmacytes. No amyloid was identi f ied. 
Rectal and left deltoid biopsies were also negative for 
amyloid. Serum protein electrophoresis revealed an 
equivocal band in the gamma region which later proved 
to be monoclonal IgE. 
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The patient was started on chemotherapy including 
v i n c r i s t i n e , 1 ,3 -b is - (2 -ch lo roe thy l ) -1 -n i t rosourea 
(BCNU), adriamycin, cyclophosphamide, melphalan, 
and p redn isone w i t h gradual imp rovemen t . Two 
months fo l lowing treatment, his urine protein and 
serum IgE level had decreased significantly (Table I). 
The patient is presently asymptomatic and is being 
fol lowed on an outpatient basis. 
Materials, Methods, and Results 
Protein studies 
Rate nephe lomet r i c quant i ta t ion of serum immu-
noglobulins using a Beckman nephelometer documen-
ted diffuse hypogammaglobulinemia wi th an IgG level 
of 586 mg/dl, IgM 34 mg/dl, and IgA 29 mg/dl. 
High resolution agarose gel electrophoresis (HRAGE) of 
serum and concentrated urine was performed on Pan-
agel slides (Worthington) consisting of 1 % agarose on 
plastic supports in barbital buffer (pH 8.6) at 200 volts for 
45 minutes. After electrophoresis was completed, the 
agarose gel was fixed in picric acid solution for ten 
minutes, rinsed in 95% ethanol, and stained in Amido 
Black. Serum protein electrophoresis showed a total 
protein level of 6.4 g/dl, albumin 4.2 g/dl, alpha-1 globu-
lin 0.3 g/dl, alpha-2 globul in 0.68 g/dl, beta globul in 0.79 
g/dl, and gamma globul in 0.48 g/dl. Retrospectively, a 
faint, equivocal band was present in the fast gamma 
region (Fig. l a ) . 
Double immunodif fusion in agar was performed ac-
cording to the method of Ouchter lony (27). The con-
centrated ur ine revealed markedly increased free 
lambda light chains wi th a trace of IgG and negative IgM 
and IgA. Double immunodi f fusion of the serum for IgE 
was positive up to a di lut ion of 1:256. 
Immunofixat ion electrophoresis (IFE) was performed by 
a modi f ied method of Ritchie and Smith (28). The 
patient's serum and pooled human control sera were 
diluted with barbital buffer (pH 8.6) to obtain a final 
protein concentration of 5 |xg/10 jxl. Three to five micro-
liters of the di luted sample were applied to the Panagel 
slides, and the proteins were separated as described 
above by HRAGE (Panagel Electrophoresis Reagent Kit 
and M ig ra t i on Un i t , W o r t h i n g t o n DR0047601 and 
DR0047602). After the electrophoresis run was com-
pleted, the gel was removed, and one Whatman #1 filter 
paper strip was laid over the cathodal port ion of each 
sample. Approximately 100-150 p.1 of antiserum against 
IgG, IgA, IgM, IgD, IgE, lambda, and kappa was evenly 
applied along the center length of each str ip, and the gel 
was incubated with the antiserum in a humidi ty cham-
ber for one hour at room temperature. The gel was 
removed, rinsed wi th saline, and pressed for 10 minutes 
using drying blotter pads. Following further washes 
with saline and deionized water and repressing be-
tween wash cycles, the slide was dried at 50°C for 10 to 15 
minutes and stained in Amido Black for 10 minutes. The 
slide was then destained in reagent grade water until the 
background was clear, b lot ted, and air dr ied. The serum 
demonstrated a broad monoclonal IgE band in the fast 
gamma region with a lambda light chain band which had 
the same migration. A second, darker staining lambda 
band, which migrated in the beta region and was ob-
scured by the C-3 component of complement in the 
HRAGE, represented free monoclonal lambda light 
chains (Fig. I b ) . 
Immunoelectrophoresis (IEP) of the serum and urine 
was carried out on agarose plates (Paragon, Beckman) 
by a modif ication of Scheidegger's method (29). The 
urine IEP demonstrated a heavy arc corresponding to 
markedly elevated lambda light chains (Fig. 2a). The 
serum displayed two abnormal arcs jo ined by a line of 
TABLE I 
Patient's Response to Chemotherapy 
Total 
Ur ine 
Protein 
(g/vol) 
Total 
Serum 
Protein 
(g/dl) 
Serum 
(mg/dl) 
Immuno 
IgG 
globulins (mg/dl) 
IgM IgA 
Bone 
Mar row 
Plasmacytosis 
(%) 
Pretherapy 5,4 6,1 50.6 
(230,000 U/ml) 
586 34 29 23.5 
2 Months 
Post-Therapy 0,6 6.3 19.8 
(90,000) 
457 30 23 9 
Normal Range 0-0,1 6.8-8.5 0-0.05 
(0-250) 
600-
1700 
50-250 60-300 0-1 
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m 
IgE, 1:2 
Lambda, 1:2 
(Hyland) 
Lambda, 1:2 
(Meloy) 
Kappa, 1:4 
Fig. 1 
A. High resolution agarose gel electrophoresis of serum demonstrates a 
faint, equivocal band (arrow) in the fast gamma region associated wi th a 
reduction of gammaglobulins. 
B. Serum immunofixation electrophoresis in agarose gel shows a broad 
monoclonal IgE band (arrow) associated wi th a monoclonal lambda spike 
(arrow) which has the same migrat ion. A second lambda band (ar-
rowhead) migrates in the region and is masked in the screening serum 
electrophoretogram by the C-3 component of complement. Staining wi th 
free and bound ant i-kappa sera reveals- di f fuse polyc lonal kappa 
light chains. 
Fig. 1 
identity; one arc signified free lambda light chains, 
and the other possibly indicated monoclonal lambda 
chains associated wi th the IgE moiety or polyclonal 
lambda chains associated wi th the IgG immunoglobul in 
(Fig. 2b). The serum also documented an abnormal arc 
precipitating with anti-IgE antiserum (Fig. 2b); the nor-
mal serum failed to form a precipit in line with this 
antiserum because of the normally low level of IgE. No 
intact immunoglobul ins were present in the urine by 
either IEP or fractional separation by Sephadex G-75 
chromatography (Pharmacia Fine Chemicals). The total 
serum IgE level as measured by solid-phase radio-
immunoassay (30) was 230,000 U/m,l (50.6 mg/dl). 
Immunohistochemistry 
Immunohistochemical localization of IgE, kappa, or 
lambda in lymphocytes was accomplished using a direct 
immunoperoxidase staining technique. Cytospin slide 
preparations of Ficoll/Hypaque mononuclear cell sus-
pensions prepared f rom bone marrow aspirate were 
used. A negative reagent control (primary antibody 
r e p l a c e d w i t h a 1:20 d i l u t i o n of H o r s e r a d i s h -
peroxidase-15 mg/10 ml PBS) and a positive tissue con-
trol slide were included in the evaluation. 
The bone marrow plasma cells d isp layed intracy-
toplasmic positivity for both IgE and lambda light chains 
(Figs. 3a,b, and c). 
Kappa 
( F + B ) 
Lambda 
(F+B) 
Fig. 2a 
Urine Immunoelectrophoresis wi th free monoclonal lambda light chains 
(arrow). 
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Discussion 
The clinical and immunochemical features of 20 cases of 
IgE myeloma are summarized in Tables II and I I I . 
The first two cases (3,4) were characterized by plasma 
cell leukemia, monoclonal light chains of the lambda 
type, and absence of bone lesions; however, sub-
sequent reports showed a much greater heterogeneity 
associated wi th this entity. The mean age at presen-
tation in this study was 61.7 years wi th a range of 48 to 77. 
No significant differences in age were present between 
men and women. Male to female ratio was almost equal 
(11:9) approximating that of IgG and IgA myeloma (31). 
The clinical features were similar to other types of mul-
tiple myeloma except for a higher frequency of hep-
atosplenomegaly (35%), which is fairly uncommon in 
myeloma (32). Bone lesions were predominant ly lytic 
(50%); however , t w o cases (10%) showed osteo-
sclerosis, a feature wh ich , when unrelated to therapy or 
pathological fracture, occurs in no more than 3% of 
Kappa 
( ) 
Lambda 
( F + B ) 
C 
P 
C 
P 
c 
p 
c 
p 
c 
Fig. 2b 
The serum Immunoelectrophoresis shows two abnormal arcs with the 
anti-lambda antiserum joined together by a line of identity. One of these 
arcs signifies free monoclonal light chains (arrow); the other signifies 
either monoclonal lambda chains bound to IgE or polyclonal lambda 
chains bound to IgG immunoglobulin (arrowhead). Also note the abnor-
mal arc precipitating with anti-IgE antiserum (arrow). 
Fig. 3a 
Direct immunoperoxidase staining of bone marrow plasma cells for 
Intracytoplasmic a) IgE, b) lambda and c) kappa immunoglobulins con-
firming IgEX, myeloma. Monoclonality is supported by the positive intracy-
toplasmic reaction to lambda light chain antiserum and negative kappa 
light chain study (direct immunoperoxidase, X 1250). 
Fig. 3b 
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patients with non-lgE type of myeloma (33-35). In this 
respect, one of the reported cases (5) remains question-
able (20) because of the appearance of the sclerotic 
lesions fol lowing melphalan therapy (36). Plasma cell 
leukemia was reported in five patients (25%), four of 
whom were men. This feature has been cited in only 1.5 
to 2% of reviewed myeloma cases (37,38) and to date 
appears to be the most characteristic feature of IgE 
myeloma (20,21). Anemia, wi th a hemoglobin level of 
less than 12 g/dl, was detected in 18 patients (90%) and 
appears to be more common and severe than in other 
myeloma types (32). 
Severe renal failure (BUN greater than 80 mg/dl) was 
found in three cases (15%). This compares to a similar 
frequency in IgG and IgA myeloma but is less than half 
as common as in light chain disease (39). Hypercalcemia 
Fig. 3c 
TABLE II 
Clinical Features of IgE Myeloma (20 Cases) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
If. 
17 
18 
19 
20 
TV ^ 
50, M 
60,M 
65,F 
51 , M 
48, F 
59, M 
57,M 
69,F 
54, M 
69,M 
64, F 
65, F 
55, F 
60, F 
77,M 
68, M 
71,F 
69, F 
67,M 
56,M 
6^ 
chest and low back pain 
fatigabil i ty, poor vision 
weakness, fat igue, nosebleed 
bone pain 
bone pain 
back pain 
weakness, headaches, b lur red vision 
hip and back pain 
pathological f racture, 
weakness, weight loss, pain 
anorexia, nausea/vomit ing, 
weight loss 
back and rib pain, weight loss 
weakness, weight loss 
epistaxis, poll inosis 
low back pain, asthenia 
chest and back pain, weight 
loss, weakness, fatigabil i ty, 
recurrent infections 
"pyonephr i t i s " 
back pain, weight loss 
Herpes Zoster infect ion 
right shoulder pain 
low back pain, weight loss, 
anorexia, nausea/vomiting 
weakness, weight loss, confusion 
progressive weakness, back pain, 
extremity and jaw weakness 
+ 
+ 
-I-
L,S 
L 
L 
L 
L,S 
L 
^ e:^ <P <P <.  
+ (61) 42 3 
+ (65) 12 4 
— 
11 5 
— 
> 2,5 6 
— 
> 6 7 
— 
>16 8 
— 
1,3 9 
— 
2 10 
+ (27) 17 11 
6 12 
— 
> 7 13 
NR 14 
+ (12) 15 
+ (20) 
6 
50 
>24 
>11 
> 4 
9 
> 2 
16 
17 
18 
19 
20 
21 
present 
case 
NR — Not reported 
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TABLE III 
Biochemical and Immunochemical Features of IgE Myeloma (20 Cases) 
if 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
10.2 
4.0 
5,0 
7,0 
6.5 
12.9 
10.1 
10.5 
6,3 
8,1 
10.5 
<8.0 
8,0 
10 
10.5 
9.4 
8,3 
10.6 
11.0 
14,2 
9,5 
12.5 
8.4 
10.1 
11.3 
8.4 
5,1 
9,5 
11.0 
10.7 
8.1 
NR 
9,9 
9,2 
8,1 
8,0 
7.6 
9,5 
10.3 
6.1 
NR 
3.18 
NR 
NL 
NR 
0.05 (g/L) 
15.1 
NR 
16 (g/L) 
3.0 
NR 
1.35 (g/L) 
1.1 (g/L) 
NR 
0.8 (g/L) 
8.6 
NR 
1.5 (g/L) 
NR 
5,4 
O <o^ <^ C^  ' 
+ 
NR 
NR 
4500 
7500 
2700 
180 
6300 
2100 
60 
2100 
2700 
4170 
2417 
5500 
4550 
3800 
1600 
3100 
1500 
3500 
2800 
50.6 
fast-7 
y 
mid-7 
p-2 
fast-7 
mid-7 
P 
NR 
fast-7 
P 
fast-7 
7 
fast-7 
fast-7 
« 
fast-7 
NR 
9,6 
9,5 
NR 
12 
NL 
8.1 
9,9 
13.4 
NL 
10.9 
NR 
9,2 
NR 
NR 
8,6 
8,1 
5,1 
NR 
9.8 
1,1 
4.4 
1.2 
NR 
1,9 
NL 
NR 
1,2 
1,8 
2.6-10 
1,2 
NR 
1.0-9.0 
NR 
2,6 
0,9 
1,2 
1,1 
6,2 
1.1 
"Al 
"Numerous" 3 
most total rep lacement" 4 
"Heavy In f i l t ra t ion" 5 
50.2 6 
50 7 
Considerable Excess" 8 
39 9 
60-100 10 
58.3 11 
>50 12 
>90 13 
"Blastic Forms" 14 
53 15 
22 and 33 16 
5 17 
72.4 18 
53.6 19 
37 20 
90 21 
23.5 present 
case 
•Def ined as light chains present in urine detected by pH indicator color imetr ic screening methods, heat test, and sulfosalicylic acid test. 
NR = not repor ted, NL = normal . 
(serum calcium greater than 11 mg/dl) was present in 
only two (14.3%) of 14 patients and is less frequent than 
in other myeloma types (40). Interestingly, of the nine 
women with IgE myeloma, five (55.6%) had a history of 
ovarian lesions which included Brenner tumor (5), cysts 
(15,20), serous papillary cystadenocarcinoma (10), and 
one case (14) in which the type of ovarian lesion was not 
repor ted . The signif icance of this is present ly not 
known. 
None of the reported cases showed any evidence of 
amyloidosis, although our case presented wi th symp-
tomatology suggestive of this disorder. The light chains 
were typed as kappa in almost three quarters of patients 
wi th IgE myeloma as compared to two thirds of patients 
wi th IgG and IgA myeloma and only one tenth of those 
wi th IgD myeloma (18,39,40). The M-protein migrated 
predominantly in the fast gamma region on zone elec-
trophoresis. The serum IgE concentration ranged f rom 
50.6 to 7500 mg/dl wi th a mean of 3056 mg/dl. Marrow 
plasmacytosis exceeded 50% in 9 of 15 cases (60%) 
where such information was documented. 
The mean survival t ime f rom diagnosis in 11 patients 
who died was 15.4 months wi th a range of 1.3 to 50 
months. Survival t ime f rom diagnosis was less than 24 
months in 9 patients. Despite a reported favorable initial 
response to chemotherapy in many patients, the aver-
age survival t ime is shorter than for IgG and IgA mye-
loma but longer than for IgD myeloma and light chain 
disease of the lambda type (31,32). Well-recognized 
features denot ing a relatively poor prognosis are similar 
to those of other types of myeloma (41,42) and include 
renal fa i lure, severe anemia, extensive skeletal in-
volvement, and Bence Jones proteinuria (16). 
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The present case is of interest because of the low level 
of M-protein in the serum (50.6 mg/dl) which was not 
initially appreciated as an M-spike on the screening 
electrophoretogram. This, coupled wi th the markedly 
elevated lambda light chains found in the urine, led to 
an initial considerat ion of l ight chain disease even 
though features commonly present in this disorder, 
such as hypercalcemia, Bence Jones proteinuria, renal 
failure, amyloidosis, and lytic bone lesions were absent 
(43). It is quite conceivable that some patients wi th IgE 
myeloma have been typed as light chain disease in the 
past (16). 
This leads to a discussion on the evaluation of mono-
clonal proteins when present in low concentrat ion. 
Traditionally, monoclonal proteins (MPs) in serum or 
urine have been studied by a combinat ion of zone 
electrophoresis and classical IEP (44,45). Recent im-
provement in the average survival of patients wi th mul-
tiple myeloma has been dependent on earlier diag-
nosis and thus less tumor cell burden and decreased 
serum MP concentration (46). It may be di f f icul t , on the 
basis of IEP analysis alone, to detect a small serum MP 
due to the l imited resolving power of this technique 
(47). O ther paraprote in iso lat ion and pur i f i ca t ion 
methods are t ime consuming and laborious. We use 
HRAGE wi th IFE in conjunct ion wi th IEP when studying 
dif f icult monoclonal gammopathies. IFE consistently 
appears to be superior to both IEP and rout ine protein 
electrophoresis for the detection and characterization 
of MPs, particularly at concentrations of less than 1000 
mg/dl (48-55). IFE offers several advantages over other 
techniques including decreased performance t ime, so 
that dif fusion leading to band broadening is kept to a 
min imum wi th resulting increased resolut ion, reduced 
reagent consumpt ion, and its easy interpretation and 
comparison to the agarose electrophoretic pattern (56). 
Closely apposed bands are easily resolved by IFE but 
may be completely lost in IEP (55-57). 
In conclusion, we have presented the clinical and im-
munochemical features of a new case of IgE myeloma 
wi th a review of the l iterature. This entity appears to be 
associated wi th an increased frequency of severe ane-
mia, less hypercalcemia and amyloidosis, a tendency to 
plasma cell leukemia and gammopathy of the kappa 
light chain type, and a shorter survival. Addit ional in-
formation awaits further documented cases. We have 
suggested the use of the more sensitive technique of 
immunofixat ion electrophoresis to study these mono-
clonal gammopathies in hope that earlier diagnosis and 
increased survival rates wil l be attained. 
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